Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.45 |
| ▸ | WNT3A | P56704 | 3/20 | 0.45 |
| ▸ | PTPRC | P08575 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30211365 | 0.86 | OPRM1 (0.48) | CYP2A6OPRM1OPRK1CTNNB1WNT3A | |
| SCHEMBL25569762 | 0.86 | OPRM1 (0.48) | CYP2A6OPRM1OPRK1CTNNB1WNT3A | |
| SCHEMBL631209 | 0.84 | CYP2A6 (0.58) | CYP2A6OPRM1OPRK1CTNNB1WNT3A | |
| SCHEMBL11098549 | 0.83 | CYP2A6 (0.53) | CYP2A6OPRM1OPRK1CTNNB1WNT3A | |
| SCHEMBL25569772 | 0.83 | CYP2A6 (0.53) | CYP2A6OPRM1OPRK1CTNNB1WNT3A | |
| SCHEMBL6398236 | 0.79 | CYP2A6 (0.51) | CYP2A6OPRM1OPRK1CTNNB1WNT3A | |
| SCHEMBL2494708 | 0.79 | CYP2A6 (0.56) | CYP2A6OPRM1OPRK1CTNNB1WNT3A | |
| SCHEMBL25569768 | 0.77 | OPRM1 (0.53) | CYP2A6OPRM1OPRK1CTNNB1WNT3A | |
| SCHEMBL1774025 | 0.76 | CYP2A6 (0.66) | CYP2A6OPRM1OPRK1CTNNB1WNT3A | |
| SCHEMBL26619319 | 0.75 | CYP2A6 (0.54) | CYP2A6CTNNB1WNT3AMRGPRX4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569466-B2 | Short-acting psychoactive compounds of the MDMA class | APOAPSIS HOLDINGS, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-20240197679-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | Altrartis Therapeutics Inc. | 2024-06-20 | — | — | US | disclosed |
| EP-4370114-A2 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | Mydecine Innovations Group Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11896577-B2 | Short-acting psychoactive compounds of the MDMA class | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230321034-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | Altrartis Therapeutics Inc. | 2023-10-12 | — | — | US | disclosed |
| US-20230321034-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | Altrartis Therapeutics Inc. | 2023-10-12 | — | — | US | disclosed |
| US-20230321034-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | Altrartis Therapeutics Inc. | 2023-10-12 | — | — | US | disclosed |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
| CN-116096715-A | Beneficial benzothiophene compositions for mental disorders or enhancement | 泰科根公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2023288013-A2 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | MYDECINE INNOVATIONS GROUP INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023288013-A2 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | MYDECINE INNOVATIONS GROUP INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| EP-1186594-B1 | N-ALKOXYALKYL-N,N-DIALKYLAMINE DERIVATIVES OR SALTS THEREOF, AND REMEDIES FOR NERVE DEGENERATION DISEASES CONTAINING THE SAME | TOYAMA CHEMICAL CO LTD (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-6797726-B1 | N-alkoxyalkyl-N,N-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| EP-1186594-A1 | N-ALKOXYALKYL-N,N-DIALKYLAMINE DERIVATIVES OR SALTS THEREOF, AND REMEDIES FOR NERVE DEGENERATION DISEASES CONTAINING THE SAME | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197679-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | PNMT, HTR2C, SLC18A2 | CYP2A6 218/4885OPRM1 22/4885OPRK1 47/4885 |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | SLC6A3, CREBBP, SLC1A2 | CYP2A6 1879/4885OPRM1 1733/4885OPRK1 1113/4885 |
| US-20230321034-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | PNMT, HTR2C, SLC18A2 | CYP2A6 218/4885OPRM1 22/4885OPRK1 47/4885 |
| US-11896577-B2 | Short-acting psychoactive compounds of the MDMA class | PNMT, HTR2C, SLC18A2 | CYP2A6 160/4885OPRM1 21/4885OPRK1 51/4885 |
| US-12569466-B2 | Short-acting psychoactive compounds of the MDMA class | HTR2C, SLC6A2, DRD2 | CYP2A6 284/4885OPRM1 8/4885OPRK1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.